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Resumo 
 
    Os inibidores de bombas de protões são uma classe de fármacos amplamente utilizada 
em várias condições patológicas, como refluxo gastroesofágico, dispepsia e úlceras 
pépticas. Apesar de existirem diversas moléculas diferentes pertencentes a esta classe, 
sabe-se que estas partilham várias propriedades funcionais e estruturais, bem como 
algumas características farmacocinéticas. O seu mecanismo de ação baseia-se na 
inibição de H+/K+ ATPases, responsáveis pela secreção de ácido gástrico. Neste 
contexto, uma vez que no processo de reabsorção os osteoclastos solubilizam a fase 
óssea mineral através da secreção de ácido para a lacuna de reabsorção por bombas de 
protões do tipo vacuolar, V-ATPases, os inibidores de bombas de protões surgem como 
potenciais modeladores farmacológicos da atividade osteoclástica, particularmente em 
condições patológicas caracterizadas pela hiperactivação de osteoclastos, tal como 
acontece nas metástases osteolíticas associadas ao cancro da mama.   
    Neste trabalho avaliaram-se os efeitos celulares e moleculares de três inibidores de 
bombas de protões, nomeadamente, omeprazole, esomeprazole e lansoprazole, em 
culturas de células do cancro da mama, em co-culturas de osteoclastos e células do 
cancro da mama e, ainda, em culturas de osteoblastos. As culturas foram mantidas na 
presença de diferentes concentrações de cada inibidor durante 21 dias. As células foram 
caracterizadas aos dias 7, 14 e 21 através da proliferação/viabilidade celular, conteúdo 
proteico, atividade e coloração histoquímica da fosfatase alcalina e da fosfatase ácida 
resistente ao tartarato, presença de células multinucleadas com anéis de actina e 
expressão de recetores de vitronectina e calcitonina, apoptose e capacidade de 
reabsorção. Posteriormente, as culturas foram também tratadas com inibidores das vias 
MAPK/ERK, NFkB, PKC e JNK para ser avaliado o envolvimento destas vias de 
sinalização intracelulares na resposta celular. Observou-se que os inibidores de bombas 
de protões inibem a osteoclastogénese em co-culturas de osteoclastos e células do 
cancro da mama, de forma dependente de dose e fármaco testado, envolvendo 
alterações significativas nas diversas vias de sinalização intracelulares testadas. 
Verificou-se, ainda, que estes compostos têm, também, a capacidade de inibir o 
crescimento de culturas de células do cancro da mama e a osteoblastogénese. Os 
inibidores de bombas de protões surgem, assim, como potenciais modeladores do 
metabolismo ósseo no contexto da metastização óssea.  
 
 
 
 
4 
 
Abstract 
 
    Proton pump inhibitors are a class of drugs widely used in many pathological 
conditions, such as gastroesophageal reflux, dyspepsia and peptic ulcers. Although there 
are several different molecules belonging to this class, it is well known that they share 
many functional and structural properties as well as some pharmacokinetic 
characteristics. The mechanism of action relies in the inhibition of H+/K+ ATPases, 
responsible for gastric acid secretion. In this context, since in the resorption process 
osteoclasts solubilize the bone mineral phase through the secretion of acid to the 
resorption lacuna by proton pumps of the vacuolar type, V-ATPases, proton pump 
inhibitors appear as potentially pharmacological modulators of osteoclastic activity, 
particularly in pathological situations characterized by hiperactivation of osteoclasts, such 
as osteolytic metastases associated with breast cancer.  
    In this study were assessed the cellular and molecular effects of three proton pump 
inhibitors, namely, omeprazole, esomeprazole and lansoprazole, in cultures of breast 
cancer cells, in co-cultures of osteoclasts and breast cancer cells and in osteoblasts 
cultures. The cultures were maintained in the presence of different concentrations of each 
inhibitor for 21 days. Cells were characterized at day 7, 14 and 21 for cellular 
proliferation/viability, total protein content, alkaline phosphatase and tartarate resistant 
acid phosphatase activity and histochemical staining, presence of multinucleated cells 
with actin rings and expression of vitronectin and calcitonin receptors, apoptosis and 
resorbing ability. Later, the cultures were treated with inhibitors of the MAPK/ERK, NFkB, 
PKC and JNK pathways to assess the involvement of these intracellular signaling 
pathways in the cellular response. Results revealed that proton pump inhibitors inhibit 
osteoclastogenesis in co-cultures of osteoclasts and breast cancer cells, depending on 
the identity and dose of the tested molecule and involving significant changes in the 
several intracellular signaling pathways tested. Moreover, it was seen that these 
compounds also have the ability to inhibit cell growth in breast cancer cell cultures and 
osteoblastogenesis. Thus, proton pump inhibitors appear as potential modulators of bone 
metabolism in the context of bone metastasis.  
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1. Introduction 
 
1.1 Bone tissue 
 
    1.1.1 Structural and functional characteristics 
 
    Bone is a specialized connective tissue that is constantly remodeling and repairing 
itself. With a microstructure developed to enable and support a maximum strength 
associated with a minimal mass, bone tissue can be divided in two components: an 
organic component, composed essentially by bone cells and an extracellular matrix 
constituted by type I collagen (90% of total protein), proteoglycans and other proteins, 
which confers flexibility; and an inorganic, or mineralized, component, composed mainly 
by calcium and phosphate salts in the form of hydroxyapatite (Ca10(P04)6(OH)2), 
representing about 60% of bone weight, and also small amounts of silicon, sodium and 
magnesium, which confers rigidity [1, 3, 18]. 
    In addition to presenting a series of mechanical functions such as, providing form, 
protection and support, the bone also acts as a reservoir, storing and releasing ions in 
order to maintain a constant concentration in body fluids, and absorbing and accumulating 
toxins and metals preventing its adverse effects in other tissues [2, 20].  
    Its multicellular base comprises essentially three distinct types of cells: osteoblasts 
(cells responsible for the formation of new bone), osteoclasts (cells specialized in bone 
resorption), and osteocytes, which are osteoblast completely embedded in bone matrix 
that are thought to play a key role as mechanosensors (Fig. 1) [2, 20].  
 
 
Figure 1.  Bone remodeling process. Osteoclasts are activated and the resorption process 
begins. Resorption phase takes approximately 10 days. Then, osteoblasts precursors are recruited, 
proliferate and differentiate. Osteoblasts produce bone mineralized matrix in a much longer 
process that can take several months.  
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 (http://www.york.ac.uk/res/btr/Image%20Library/Bone%20remodelling.jpg) 
 
    Once formed, bone performs its remodeling process balancing these actions of bone 
resorption and synthesis in order to ensure the renewal of tissue with minimal temporary 
loss. Unbalances between these actions can result in some pathological conditions. Most 
adult skeletal diseases are caused by an excess of osteoclastic activity, such as 
osteoporosis and rheumatoid arthritis [1]. 
 
    1.1.2 Bone cells 
 
    1.1.2.1 Osteoblasts 
 
    Osteoblasts arise from mesenchymal stem cells (MSC) and are the bone-forming cells. 
The process of differentiation of osteoblasts is less well understood than the osteoclastic 
one. 
 
    First, mesenchymal stem cells are committed to the osteoblast lineage. These cells, 
called osteoprogenitors, proliferate and differentiate into pre-osteoblasts. Pre-osteoblasts 
in turn start to produce extracellular matrix (ECM) and differentiate into mature 
osteoblasts. Mature osteoblasts ensure ECM synthesis and mineralization. However, only 
a fraction of the mature osteoblasts will be incorporated into newly formed bone matrix 
and remain as osteocytes. The remaining osteoblasts will die or become lining cells (Fig. 
2) [17]. 
 
 
Figure 2. Stages of osteoblasts differentiation. Osteoblasts undergo a complex differentiation 
process that essentially comprises: cell proliferation, matrix maturation and matrix mineralization. 
(Adapted from Aubin, J. E. et al.) 
  
    During the active proliferation phase, committed progenitor cells express genes that 
support proliferation and several genes encoding for extracellular matrix proteins, such as 
type I collagen and fibronectin. The accumulation of matrix proteins will contribute, in part, 
to the cessation of cell proliferation. During the post-proliferative phase, characterized by 
the high synthesis of alkaline phosphatase (ALP), the extracellular matrix progresses to 
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the mineralization phase. Here, osteoblasts synthesize several proteins that are 
associated with the mineralized matrix, including sialoprotein, osteopontin and osteocalcin 
[14, 15, 16].  
    It is believed that each of the differentiation steps during osteoblastogenesis is 
regulated by different kinds of morphogens, hormones, growth factors, cytokines and 
ECM proteins [12, 13]. 
 
    1.1.2.2 Osteoclasts  
 
    Osteoclasts are mobile multinucleated cells that arise from precursor cells in the CD14+ 
monocyte-macrophage lineage [1, 23]. The osteoclast precursor cells reach the bone 
through the blood circulation and fuse into multinucleated cells to form mature osteoclasts 
in a process called osteoclastogenesis. Inactive osteoclasts adhere to bone surface 
through specialized adhesion structures called podosomes, forming a sealing zone sealed 
by actin filaments together with αvβ3 integrin, the vitronectin receptor (VNR) [20-22]. 
    Once formed, the resorption lacuna, or Howship’s lacuna, is acidified by the export of 
hydrogen ions mediated by H+-ATPase located in osteoclasts plasma membrane. These 
protons are derived from the carbonic acid formed by solubilization of CO2 by carbonic 
anhydrase II (CA2). Thus, mineral phase is dissolved by H+ action, producing and 
releasing into the resorption lacuna calcium, water and phosphate, according to the 
following equation [9, 20, 21, 75]. 
 
[Ca3(PO4)2]3Ca(OH)2 + 8 H
+  →  10 Ca2+ + 6 HPO4+ 2 H2O 
 
Hydroxyapatite (solid)                            (solution) 
 
    The process continues with the degradation of the organic phase, being carried out 
through the action of lytic enzymes such as tartarate resistant acid phosphatase (TRAP) 
and cathepsin K (CATK), both secreted by osteoclasts (Fig. 3) [9, 20, 21]. 
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Figure 3. Functional elements of the mature osteoclast.  Osteoclasts adhere to bone via 
podosomes containing αvβ3 integrin. Protons generated by action of CA2 are transported into the 
resorption lacuna by the vacuolar-type H
+
-ATPase. CATK is an important enzyme for the removal 
of the organic components of bone in the resorption lacuna. (Adapted from Tolar, J. et al.) 
 
    1.1.3 Osteoclastogenesis 
 
    Osteoclastogenesis is a complex process regulated by different cells, such as 
osteoblasts and bone marrow stromal cells, responsible for the production of many 
modulators of the process, including the two key protein factors that shape osteoclast 
differentiation and activation, namely macrophage colony stimulating factor (M-CSF) and 
receptor activator of nuclear factor kB ligand (RANKL) [1, 2, 23]. 
 
    M-CSF is a homodimeric glycoprotein produced by monocytes, granulocytes, 
endothelial cells, osteoblasts, fibroblasts, lymphocytes B and T, and some tumor cell lines. 
M-CSF promotes the formation of granulocytes and macrophages colonies and acts on 
osteoclastogenesis at an early stage in the fusion and further differentiation of monocytes 
[19, 24-26]. RANKL is a homotrimeric protein member of the tumor necrosis factor (TNF) 
family that stimulates differentiation and activation of osteoclasts by linkage to RANK 
receptor on the surface of precursor cells.  RANKL is produced by osteoblasts but it can 
also be synthesized by fibroblasts, lymphocytes T and bone marrow cells. 
  
    The osteoclastogenic process may, however, be negatively regulated by 
osteoprotegerin (OPG) which, acting as a soluble receptor to RANKL, prevents RANKL-
RANK binding, decreasing its bioavailability [1, 19, 27-30].  
 
    M-CSF and RANKL are, by themselves, enough to induce the expression of several 
osteoclastic features, such as the reorganization of the cytoskeleton with formation of 
actin rings that establish the contact with the resorption lacuna, production of TRAP, 
enzyme used as a marker of osteoclastic activity, synthesis of VNR, responsible for the 
adhesion process, and calcitonin receptor (CTR) of which the ligand is an inhibitory 
hormone of the osteoclastic activity, preserving bone mass (Fig.4) [1, 31]. 
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Figure 4. Osteoclastogenesis. M-CSF and RANKL act in crucial phases of osteoclastogenesis, 
being able to induce the expression of several osteoclastic characteristics. (Adapted from Feng, X.) 
 
    Upon resorption, bone-stored growth factors, such as bone morphogenetic proteins 
(BMPs), insulin-like growth factors (IGFs), and transforming growth factor-betas (TGF-β), 
are released and activated. These local factors, along with the systemic factors 
parathyroid hormone (PTH), estrogens, and prostaglandins, are constantly released in the 
bone marrow cavity by osteoclastic bone resorption, and recruit new osteoblasts to fill the 
gap created by osteoclasts [47]. 
 
    1.1.4 Hormonal control 
 
    PTH (parathyroid hormone) is a peptide produced by the parathyroid glands that is 
important in the maintenance of normal calcium homeostasis due to its stimulatory effects 
on osteoclastic bone resorptive activity and renal reabsorption of calcium [32].  
    Parathyroid hormone related protein (PTHrP) binds PTH receptor and activates adenyl 
cyclase to produce cyclic adenosine monophosphate (cAMP). The effects of PTH and 
PTHrP on osteoclasts and precursors were studied in vivo. These studies demonstrated 
that neither PTH nor PTHrP had an effect on early osteoclast precursors, but increased 
the number of committed mononuclear osteoclast progenitors as well as mature 
osteoclasts [32].  
 
    However, the primary target cell for PTH appears to be the osteoblast. PTH binds to 
osteoblasts stimulating osteoblasts to increase their expression of RANKL and to inhibit 
their expression of OPG. Isolated osteoclasts seem to not resorb bone in response to 
PTH and only do so when osteoblasts or osteoblastic cell lines are added to the cultures. 
Furthermore, PTH induces RANKL expression by marrow stromal cells. On the other 
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hand, PTHrP stimulates bone formation by enhancing osteoblast differentiation and 
reducing osteoblast apoptosis (Fig. 5) [33]. 
 
     
 
Figure 5. Regulation of Bone Resorption. Both systemic factors and locally acting factors induce 
the formation and activity of osteoclasts. Systemic hormones such as parathyroid hormone, 1,25-
dihydroxyvitamin D 3, and thyroxine (T 4) stimulate the formation of osteoclasts by inducing the 
expression of RANKL on marrow stromal cells and osteoblasts. In addition, osteoblasts produce 
interleukin-6 (IL-6), interleukin-1 (IL-1), prostaglandins, and colony-stimulating factors (CSFs), 
which induce the formation of osteoclasts. (Adapted from Roodman, G. D.)  
 
    1.1.5 Signaling pathways 
 
    Osteoclastogenesis is an extremely complex process dependent on the action of 
several hormones, growth factors, and others, therefore involving multiple intracellular 
signaling pathways.  
 
    Several signaling pathways are activated by RANKL mediated protein kinase signaling. 
Some of them mediate directly osteoclastogenesis and others osteoclast activation. The 
intracellular domain of RANK contains three binding domains for TNF receptor-associated 
factors (TRAF). TRAF2, -5 and -6 have been shown to bind to RANK and studies revealed 
that TRAF6 is indeed an essential adaptor required for RANK-associated signaling (Fig. 6) 
[10, 34]. 
 
    Among the major types of signal transduction pathways in eukaryotic cells are protein 
kinase cascades which culminate in the activation of a family of protein kinases known as 
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mitogen activated protein kinases, or MAP kinases. Although they vary in their substrate 
specificities and responses to extracellular stimuli, MAP kinases are highly conserved in 
their primary structure and mode of activation. All MAP kinases are serine/threonine 
kinases that are activated in response to their phosphorylation on invariant threonine and 
tyrosine residues [36]. The mitogen activated protein kinase and extracellular signal 
regulated kinase (MAPK/ERK) pathway triggers intracellular responses through binding of 
growth factors to surface receptors promoting osteoclastic proliferation and differentiation 
[35].  
    Recently, Miyazaki et al. reported that ERK is involved in survival of osteoclasts by 
showing that inhibition of ERK activity induced the apoptosis of osteoclast-like cells while 
ERK activation remarkably lengthened their survival by preventing spontaneous 
apoptosis. In short, results show that ERK is localized in the clear zones of osteoclasts. It 
seems that both the prevention of ruffled border formation and the acceleration of 
apoptosis in osteoclasts are associated with a decrease in phosphorylated ERK. Results 
suggest that ERK in osteoclasts may be involved in their survival, motility, and cell polarity 
[35]. 
 
    Nuclear factor kappa B (NF-kB) is a family of five transcription factors that are 
expressed in most cell types. NF-κB dimers are normally inactive in the cytosol. Activation 
of this transcription factor is a consequence of phosphorylation of its inhibitory protein, IκB 
proteins (IκBa, IκBb, IκBe, IκBg, Bcl-3), by an upstream kinase complex termed IκB kinase 
(IKK), resulting in the release and translocation of NF-κB to the nuclear compartment. 
Once in the nucleus, they attach to κB binding sites in the promoter region of a large 
number of genes including IL-1, IL-6, TNFα-, and granulocyte macrophage colony-
stimulating factor (GMCSF) and, after stimuli-induced IκB protein degradation in response 
to extracellular signals, induce their transcription [37]. Thus, NF-kB pathway regulates the 
expression of various genes essential to inflammatory and immune responses, by 
regulating the expression of a variety of pro inflammatory cytokines and other 
inflammatory mediators, cellular survival and proliferation.  It is crucial for 
osteoclastogenesis in terms of differentiation of monocytic precursors into osteoclasts and 
further activation such as the C-jun N-terminal kinase (JNK) pathway, which acts 
mobilizing a series of osteoclastogenic transcription factors [5, 6, 8]. JNK is a subgroup of 
the MAPK family and is also known to be activated by cell stressors such UV radiation 
[36]. 
 
    Other relevant signaling pathways are protein kinase C (PKC) and stress-activated 
protein kinase (p38). PKC pathway when activated induces cellular proliferation, apoptosis 
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and actin remodeling. Stimulation of the stress-activated protein kinase, p38, results in the 
downstream activation of the microphthalmia associated transcription factor (MITF), which 
controls the expression of the genes encoding TRAP and CATK, required for osteoclastic 
function [4, 7]. 
 
Figure 6. Signaling pathways involved on osteoclastogenic differentiation. Binding of RANKL 
to its receptor RANK induces various intracellular signaling cascades, such as MAPK (JNK, ERK, 
MAPK 14) and NF-κB. Several transcription factors have been found crucial for osteoclast 
differentiation downstream of RANKL/RANK signaling. (Adapted from Edwards, J. R. and Mundy, 
G. R.) 
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1.2 Breast cancer 
 
    1.2.1 Epidemiology and pathology  
 
    Breast cancer is by far the most frequent cancer among women (small occurrence in 
men) with an estimated 1.38 million new cancer cases diagnosed in 2008 (23% of all 
cancers), and ranks second overall (10.9% of all cancers). It is now the most common 
cancer both in developed and developing regions and it is second only to lung cancer as a 
cause of cancer mortality. 
    It is estimated that in the year of 2008, the incidence rate of breast cancer in Portugal 
was 60 per 100,000 and the mortality rate of 13.5 per 100,000 [GLOBOCAN 2008 IARC].  
 
    Ninety-five percent of breast cancers are carcinomas. Carcinomas can be divided into: 
in situ carcinoma and invasive or infiltrating carcinoma, and these may arise either in 
ducts or lobules. Most carcinomas show ductal differentiation (90%). Other malignant 
lesions are associated with mesenchymal neoplasms, such as cystosarcoma phyllodes, 
angiosarcoma, among others [38, 39]. 
 
 
Figure 7. The female breast. The anatomic structures and lesions of the female breast. 
(http://medicinembbs.blogspot.pt/2010/12/breast-anatomy.html)  
 
Benign lesions include hyperplasia, cystic changes, adenomas, papillomas and 
fibroadenomas, the most common benign tumor of the breast. Pathologies of the adipose 
tissue can also occur, called traumatic fat necrosis (Fig. 7) [38, 39].  
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    1.2.2 Risk factors  
  
    There are several risk factors considered for the development of breast cancer. 
Obviously, the age and the occurrence of a prior breast cancer or benign lesion are two of 
them, but there is also a number of lifestyle, environmental and hormonal factors that are 
probably involved (unbalanced diet, lack of exercise, early menarche, hormone 
replacement therapy, nulliparity, …) [38, 39,40].  
    Women with a family history of breast cancer should obtain as much information as 
possible about those relatives, including age at onset and type of cancer. The risk of 
breast cancer development related to family history increases with the number of affected 
relatives, specific lineage and age at diagnosis [38, 39, 40].  
    About 5-10% of breast cancer is thought to be linked to changes in certain genes. The 
most common are those of the BRCA1 and BRCA2 genes. Women with mutations in 
these genes have a higher risk of developing breast and ovarian cancer during their lives 
[38, 39, 40].     
 
    Despite advances, 20-30% of patients with early breast cancers experience relapse 
with distant metastatic disease. Risk of recurrence is influenced by stage at initial 
presentation and the underlying biology of the tumor. Tumor size, nodal involvement, 
grade, lymphovascular invasion, and estrogen receptor (ER) and human epidermal growth 
factor receptor 2 (HER2/erB2) status are all independent risk factors for relapse [38, 39, 
59].  
 
    1.2.3 Molecular types of breast cancer  
 
    The heterogeneity of breast cancers makes them both a fascinating and challenging 
solid tumor to diagnose and treat. 
 
    Until very recently, personalized cancer medicine in breast cancer relied on only two 
predictive markers, ER and HER2/erB2. Breast cancer is now recognized not as a single 
disease with variable morphology, but as at least four molecularly distinct neoplastic 
disorders: luminal-A breast cancer (low proliferative ER positive), luminal-B breast cancer 
(high proliferative ER positive), HER2-positive breast cancer (amplification and high 
expression of the ERBB2 gene and several other genes of the ERBB2 amplicon) and 
triple-negative or basal-like breast cancer (ER/progesterone receptor negative and HER-
2-negative) (Fig. 8) [41, 42]. 
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    Although the immediate additional clinical value of this molecular classification is limited 
by its close correlation to traditional methods of testing for ER and HER2, the identification 
of genetic aberrations that underlie molecularly distinct subtypes of breast cancer has 
revealed new therapeutic targets and has reshaped breast cancer clinical trial design [41, 
42]. 
                   
Figure 8. Molecular types of breast cancer.  To distinguish the molecular type of cancer, first 
HER2 membrane receptor must be assessed and only after test for nuclear hormone receptor. Ki 
67 denotes nuclear antigen ki-67, a marker of cell proliferation.  (Adapted from Sotiriou, C. and 
Pusztai, L.) 
 
    Estrogen receptor/progesterone receptor positive (ER/PR+) tumors have a better 
prognosis and a better response to treatment than receptor-negative tumors. Two thirds of 
women with diagnosed breast cancer have ER/PR+ tumors. These tumors are highly 
responsive to anti-estrogen therapeutic strategies. However, despite the widespread use 
of hormonal adjuvant therapy, a quarter of women with ER+ disease will relapse. Since 
the earliest studies of the intrinsic molecular subtypes in breast cancer, the defining 
feature of luminal- B breast cancer has been its poor outcome compared with the luminal-
A subtype. Several studies have suggested that luminal-B breast cancer is relatively 
insensitive to endocrine therapy compared with luminal-A [43, 49]. 
 
    HER2 is over expressed in 15-20% of breast cancer, and it is associated with a highly 
aggressive behavior. HER family is constituted by four members, HER1, HER2, HER3 
and HER4. An intracellular tyrosine kinase domain exists for HER1, HER2 and HER4 and 
phosphorylation of these domains by homodimerization or heterodimerization induces 
both cell proliferation and survival signaling [61]. HER2 is the preferred dimerization 
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partner for the other HER family members. One of the other downstream effects of these 
reactions is the production of vascular endothelial growth factor (VEGF) supporting 
angiogenesis [58].  
The availability of the anti-HER2 monoclonal antibody therapy has significantly improved 
the prognosis of patients with HER2 positive breast cancer both in early and advanced 
disease stages. 
 
    Triple-negative breast cancers in particular are difficult to define. This tumor subgroup 
does not respond to hormonal therapies or Her2-targeted therapies due to the lack of 
expression of these targets. These tumors are associated with a poor prognosis. 
     The subtypes most in need of therapeutic advances are triple negative breast cancer 
and luminal-B breast cancer, where therapeutic resistance is common and where 
advances in molecular profiling have identified promising new therapeutic targets [43, 49]. 
 
    1.2.4 Therapies 
 
    Breast cancer surgery has changed dramatically over the past 20 years. With the 
emergence of breast conserving therapy, many women now have the option of preserving 
a cosmetically acceptable breast without sacrificing survival. Conserving therapy refers to 
surgical removal of the tumor without removing excessive amounts of normal breast 
tissue. The aims of this therapy are to provide a cancer operation equivalent to 
mastectomy and a cosmetically acceptable breast, with a low rate of recurrence in the 
treated breast. The main obstacle to widespread acceptance and utilization of conserving 
therapy is the risk of in-breast recurrence. Depending of several factors, such as tumor 
size, multifocality and possibility of radiotherapy used, mastectomy may be the method of 
choice. Regardless of the method used, axillary lymph node dissection is always 
mandatory for evaluation [39, 40].  
 
    Radiation adjuvant therapy is known to substantially reduce the risk of recurrence and 
decrease breast cancer mortality, both when given after mastectomy and after breast-
conserving surgery. Radiation therapy is generally given over a 5- or 6-week time span, 
with care taken to try to avoid damage to the heart or lungs. The only usual changes with 
breast radiation are skin erythema and possibly some transient lymphedema [39]. 
 
    Adjuvant systemic therapy refers to the administration of chemotherapy, hormone 
therapy and/or monoclonal antibodies used following primary surgery for breast cancer. 
The purpose is to eliminate or delay the subsequent appearance of clinically occult 
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micrometastases. The original regimen of chemotherapy used was cyclophosphamide, 
methotrexate, 5-fluorouracil (CMF). Thereafter, many other regimes have been used. A 
major determinant of the choice of adjuvant therapy is whether an individual breast cancer 
expresses hormonal receptors (HR). Hormone therapy benefits patients with hormone 
receptor-positive breast cancer, but not those with hormone receptor negative disease 
[39]. 
 
    Targeting the ER is the oldest molecular targeted therapy approach, and the 
widespread use of the selective ER modulator tamoxifen in breast cancer is responsible 
for major improvements in cure rates, quality of life and disease prevention for the past 25 
years [39, 40]. 
 
    Tamoxifen, a selective estrogen receptor modulator (SERM), inhibits the growth of 
breast cancer cells by competitive antagonism of estrogen at the ER, inhibiting both 
translocation and nuclear binding of the ER. Tamoxifen and its metabolites bind to the ER, 
and subsequently occurs translocation of this complex to the nucleus and binding to the 
estrogen-response element. This binding prevents transcriptional activation of estrogen-
responsive genes (Fig. 8). However, its actions are complex and it has also a partial 
estrogen agonist activity. Additionally, there are marked differences between the anti 
proliferative properties of tamoxifen and its metabolites [40, 57].  
 
    Their long-term efficacy, however, is limited by relapse of disease and development of 
resistance. Laboratory and clinical data have demonstrated that ER-positive breast 
cancers that overexpress HER2 are associated with resistance to tamoxifen and to 
hormonal therapy in general. Despite continuous expression of ER at relapse in either 
locally recurrent or secondary metastatic tumors, up to half of patients with HR-positive 
primary breast cancer who develop metastatic disease do not respond to first-line 
endocrine treatment (de novo resistance), and the remainder will eventually relapse 
despite an initial response (acquired resistance) [40]. 
 
    Several factors may contribute to tamoxifen resistance in breast cancer, including 
variable expression of estrogen receptor alpha and beta isoforms, interference with 
binding of co-activators and co-repressors, alternatively spliced ER mRNA variants and 
ER modulators expression, such as epidermal growth factor (EGF) and its receptor 
(EGFR1, also called HER1), as well as the type 2 EGFR, also called HER2. Emerging 
studies also suggest that relative resistance to tamoxifen may be related to inheritance of 
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certain drug metabolizing CYP2D6 genotypes that are associated with a reduced 
activation of tamoxifen to its active metabolite endoxifen [40, 44, 60]. 
 
    Other hormonal therapeutic agents include aromatase inhibitors that interfere with the 
enzyme aromatase, which plays a critical role in the production of estrogen in 
postmenopausal women. Aromatase is an enzyme that naturally converts estrogen from 
androgen. In premenopausal women, most of the estrogen is produced in the ovaries, but 
in postmenopausal women, most estrogen is synthesized in peripheral tissue from 
conversion of androgens. In contrast to tamoxifen, these compounds lack partial agonist 
activity (Fig. 9). Examples of this class include anastrozole, letrozole and exemestane [40, 
45]. 
 
Figure 9. Comparison of the mechanisms of action of estradiol, tamoxifen and aromatase inhibitors.  
Estradiol binds to ER, leading to dimerization, conformational change and binding to estrogen response 
elements (ERE) upstream of estrogen responsive genes including those responsible for proliferation. 
Tamoxifen competes with estradiol for ER binding whereas Aromatase inhibitors reduce the synthesis of 
estrogen from androgenic precursors. (Adapted from Johnston, S. R. D. and Dowsett, M.)  
 
    Approximately 25-30% of breast cancer tumours display amplification of the HER2 
gene or overexpression of its protein product, and this is associated with an adverse 
prognosis. Trastuzumab is a humanized monoclonal antibody directed against the 
external domain of the receptor with clinical activity as a single agent in patients whose 
cancers overexpress HER2 (Fig. 10). Overexpression of the receptor is associated with 
increased disease recurrence and worse prognosis. Targeting both HER2 with 
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trastuzumab and VEGF with bevacizumab in combination with chemotherapy has become 
a further milestone of molecular targeted therapy. However, intrinsic and acquired 
resistance to endocrine and/or cytostatic treatments is still a common feature that limits 
the benefits of these novel therapeutic strategies. In tumors that are HER2 and ER 
positive, HER2 signaling is dominant. This resistance can be partially overcome by 
combining anti-estrogen and anti-HER2 therapies [40, 57, 61]. 
 
 
Figure 10. Potencial mechanisms of action of transtuzumab. Cleavage of the extracellular 
domain of HER2 leaves a membrane-bound phosphorylated p95, which can activate signal-
transduction pathways. Binding of trastuzumab to a juxtamembrane domain of HER2 reduces the 
release of the extracellular domain, thereby reducing p95. Trastuzumab may reduce HER2 
signaling by physically inhibit homodimerization or heterodimerization. Trastuzumab may also 
recruit immune effector cells and other components of antibody-dependent cell-mediated 
cytotoxicity, leading to tumor-cell death. Other mechanisms such as receptor down-regulation 
through endocytosis have been suggested. (Adapted from Hudis, C. A.) 
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1.3 Bone metastasis in breast cancer 
 
   1.3.1 Bone metastasis 
 
    Most patients with cancer die not because of the primary tumour, but rather because it 
has spread to other sites. It is difficult to determine, precisely, how frequently different 
tumours metastasize to bone. Patients with advanced breast and prostate cancers almost 
always develop bone metastases. Moreover, the chances are high that, in patients who 
are originally diagnosed with breast or prostate cancers, the bulk of the tumour burden at 
the time of death will be in bone [46]. Metastasis to bone occurs in the late stages of 
tumor progression, in a multistep process [50, 51].  
 
    Because tumor metastasis is a complex process involving individual discrete steps, 
interruption of one or more of these steps can inhibit the metastatic process. Each of 
these steps represents cellular interactions caused by specific determinants of both the 
tumor and the tissue. The steps involved in the shedding of the tumor cells from the 
primary site involve detachment of tumor cells from adjacent cells, followed by invasion of 
adjacent tissue in the primary organs. The cells then enter the tumor capillaries 
(stimulated by specific angiogenesis factors produced by the tumor) and via these 
capillaries reach the general circulation. The steps involved in entering the tumor blood 
vessels at the primary site are similar to those involved in exiting the vasculature in the 
bone marrow cavity. These steps include the attachment of the tumor cells to basement 
membrane, the secretion of proteolytic enzymes that enable tumor cells to disrupt that 
membrane, and the migration of the tumor cells through it. Tumor cells that metastasize to 
the skeleton adhere to the endosteal surface and colonize bone (Fig. 11) [50, 51]. 
 
 
Figure 11. The steps involved in tumour-cell metastasis from a primary site to the skeleton. 
The primary malignant neoplasm promotes new blood-vessel formation, and these blood vessels 
25 
 
carry the cancer cells to capillary beds in bone. Aggregates of tumour cells and other blood cells 
eventually form embolisms that arrest in distant capillaries in bone. These cancer cells can then 
adhere to the vascular endothelial cells to escape the blood vessels. As they enter the bone, they 
are exposed to factors of the microenvironment that support growth of metastases. (Adapted from 
Mundy, G. R.) 
 
    Although the distribution of metastases in distant organs can be predicted by the 
anatomic distribution of blood flow from the primary site in 30% of cases, specific 
properties of the tumor cell and features at the metastatic site determine where the 
metastasis occurs in the majority of cases [51].  
 
    The metastasis of tumor cells to specific sites in the skeleton is not a simple and 
random event determined solely by blood flow. Rather, it is a complex process that is 
dependent on specific properties of the tumor cells and on factors in the bone 
microenvironment that favor metastasis. Tumor cells most frequently affect the heavily 
vascularized areas of the skeleton, particularly the red bone marrow of the axial skeleton 
and the proximal ends of the long bones, the ribs, and the vertebral column [51]. 
 
    Physical factors within the bone microenvironment, including low oxygen levels, acidic 
pH, and high extracellular calcium concentrations, may also enhance tumor growth.  
 
    Hypoxia is a major contributor to tumor metastasis, regulating secreted products that 
drive tumor-cell proliferation and spread. Hypoxia also contributes to resistance to 
radiation and chemotherapy in primary tumors. Solid tumors are particularly prone to 
hypoxia because they proliferate rapidly, outgrowing the malformed tumor vasculature, 
which is unable to meet the increasing metabolic demands of the expanding tumor. 
Hypoxia regulates normal marrow hematopoiesis and chondrocyte differentiation. Cancer 
cells capable of surviving at low oxygen levels can thrive in the hypoxic bone 
microenvironment and participate in the vicious cycle of bone metastasis [50]. 
 
    Acidosis of the bone microenvironment also potentiates the vicious cycle of bone 
metastasis. Extracellular pH is tightly regulated within bone and has significant effects on 
osteoblast and osteoclast function with osteoclasts being maximally stimulated at pH 
levels of <6.9. Osteoblast mineralization and bone formation is significantly affected by 
acid. Tumor metastasis leads to localized regions of acidosis within the skeleton. 
Increased glycolysis and lactic acid production by proliferating cancer cells (due to the 
hypoxic conditions) and decreased buffering capacity of the interstitial fluid contribute to 
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the acidic microenvironment within primary tumors. The acid-mediated tumor invasion 
hypothesis states that altered glucose metabolism in cancer cells stimulates cancer cell 
proliferation resulting in a more invasive tumor phenotype. Acidosis alters the cellular 
dynamics at the interface between the tumor and normal tissue, promoting apoptosis in 
adjacent normal cells and facilitating extracellular matrix degradation through the release 
of proteolytic enzymes. Unlike normal cells, cancer cells have compensatory mechanisms 
to allow proliferation and metastasis even at low extracellular pH, being resistant to acid-
induced apoptosis [50]. 
 
    Calcium released from the mineralized bone matrix contributes to the vicious cycle of 
metastasis by several mechanisms. Calcium is the primary inorganic component of the 
bone matrix and, in the bone microenvironment, levels are maintained within a narrow 
physiologic range. Active osteoclastic bone resorption causes extracellular calcium levels 
to rise up. The effects of Ca2+ are mediated through the extracellular calcium-sensing 
receptor (CaSR), a G protein–coupled receptor, which, in the presence of high Ca2+, 
inhibits cyclic AMP and activates phospholipase C. The CaSR is expressed in normal 
tissues and is overexpressed in several types of cancer, including breast and prostate 
cancer and it regulates the secretion of PTHrP [50]. 
 
    Finally, estimates of the frequency of metastasis depend also on the sensitivity of the 
diagnostic technique utilized to detect them. The most commonly used techniques are 
bone scans, X-rays, and histologic evaluation of autopsy specimens. Both radiologic and 
histologic assessments are limited by the extent of the sample evaluated. Bone scans 
survey the whole body. However, because isotope accumulation depends on osteoblast 
activity, lesions with very little osteoblastic component cannot be detected [51]. 
 
    1.3.2 Types of bone metastases 
 
    There are different patterns of bone effects in patients with cancer, ranging from purely 
or mostly destructive, designated by osteolytic metastases, to mostly bone-forming or 
osteoblastic metastases [46]. However, patients can have both osteolytic and osteoblastic 
metastasis or mixed lesions containing both elements. Both osteoblastic and osteolytic 
bone metastases lead to numerous skeletal complications, including bone pain, 
hypercalcemia, pathologic fractures, and spinal cord and nerve compression syndromes. 
Such complications increase morbidity and diminish the quality of life in these patients [47, 
63]. 
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    Breast cancer is one of the most frequent tumours that originate bone metastasis, being 
the most common the osteolytic ones. However, 15 to 20 percent of the patients have 
predominantly osteoblastic lesions. Moreover, secondary formation of bone occurs in 
response to bone destruction. This reactive process makes it possible to detect the 
osteolytic lesions by scanning techniques, identifying the sites of active bone formation 
[47]. This increase in bone formation in patients with osteolytic lesions can be also 
reflected by the increase of serum ALP levels, a marker of osteoblasts activity. In contrast, 
the lesions in prostate cancer are predominantly osteoblastic.  
    In breast cancer, osteolytic bone metastasis results from a hiperactivation of 
osteoclasts induced directly or indirectly by several factors produced by cancer cells. 
Osteoblastic metastases, conversely, are believed to be caused by cancer-cell production 
of factors that stimulate osteoblast proliferation, differentiation and bone formation [46, 
63]. 
 
    1.3.2.1 Osteoblastic metastases 
  
    The mechanisms of osteoblastic metastasis and the factors involved are unknown. 
Endothelin-1 has been implicated in osteoblastic metastasis from breast cancer. This 
molecule is one of the most well studied mediators that stimulates bone formation and 
osteoblast proliferation in bone organ cultures. Endothelin-1 levels are increased in the 
circulation of patients with osteoblastic metastases and prostate cancer, being also 
expressed by breast cancer cell lines that cause osteoblastic metastases. Osteoblast 
proliferation and bone metastasis have both been shown to be inhibited in vivo by 
endothelin-1A-receptor antagonists. In addition to endothelin-1, platelet-derived growth 
factor (PDGF), a polypeptide produced by osteoblasts in the bone microenvironment, 
urokinase, and prostate- specific antigen may also be involved [47, 93]. 
 
    1.3.2.2 Osteolytic metastases 
     
    Breast cancer cells produce factors that direct or indirectly induce osteoclasts 
formation. In turn, bone resorption carried out by osteoclasts release growth factors from 
bone matrix which stimulate tumor growth and bone destruction. This reciprocal 
interaction between breast-cancer cells and the bone microenvironment results in a 
vicious cycle that increases both bone destruction and the tumor burden [47, 64].  
 
    Bone is an abundant source of inactive growth factors which are activated during the 
resorption process, including TGF-β, IGFs I and II, fibroblasts growth factors (FGFs), 
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PDGFs, BMPs and calcium. These factors are then released providing a fertile ground in 
which tumour cells can grow. On the other hand, breast cancer cells and many of other 
solid tumours are thought to stimulate the formation of osteoclasts by the production of 
PTHrP. This molecule, in association with other factors produced by tumor cells, such as 
IL-6, prostaglandin E2 (PGE2), TNF-α (tumour necrosis factor α) and M-CSF, increase the 
expression of RANKL mainly by osteoblasts, which directly acts on osteoclast precursors 
promoting osteoclastogenesis and bone resorption (Fig. 12) [46, 47, 63, 64].  
 
 
Figure 12. The Vicious Cycle of Osteolytic Metastasis. Breast-cancer cells, secrete PTHrP as 
the primary stimulator of osteoclastogenesis. In addition, tumor cells produce other factors that 
increase the formation of osteoclasts (IL-6, PGE2, TNF-α, and M-CSF). All these factors increase 
the expression of RANKL. The process of bone resorption releases factors such as TGF-b,IGFs, 
FGFs, PDGF, and BMPs, which increase the production of PTHrP by tumor cells as well as growth 
factors that increase tumor growth. This symbiotic relationship between bone destruction and tumor 
growth further increases bone destruction and tumor growth. (Adapted from Roodman, G. D.) 
 
    Two pieces of evidence support the view that osteoclastic bone resorption is the 
predominant mechanism of bone destruction in bone metastasis: histological analysis and 
scanning electron microscopy studies invariably detect tumor cells adjacent to osteoclasts 
resorbing bone, and the use of bisphosphonates, potent inhibitors of osteoclastic bone 
resorption, in women with breast cancer metastases to bone results in reduced skeletal 
morbidity [51].  
 
    1.3.3 Molecular types of breast cancer and metastatic behavior 
 
    It is known that estrogen-responsive breast cancer cells have a more aggressive bone 
metastatic behavior than their estrogen receptor-negative counterparts which metastasize 
more aggressively to visceral organs (liver, lung, pleura…). There are differences in the 
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anatomic sites of relapse according to molecular subtypes. The increased incidence of 
brain metastases in HER2-positive and basal like breast cancer is well recognized. 
Luminal breast cancers appear to have a predilection for metastasis to bone and pleura. 
In a small study of patients with metastatic breast cancer, no differences in sites of 
metastasis were observed between luminal-B and luminal-A breast cancers.  
 
    1.3.4 Treatment 
 
    Bisphosphonates (BPs) are a class of pyrophosphate analogues that bind with high 
affinity to mineralized bone surfaces and inhibit osteoclastic bone resorption. Common 
examples of these drugs are pamidronate (Aredia), alendronate (Fosamax), zoledronate 
(Zometa), risedronate (Actonel) and clodronate (Bonefos) [46]. Bisphosphonates are used 
extensively to treat patients with diseases associated with bone loss, such as 
osteoporosis, Paget’s disease and osteolytic metastasis [54, 55]. 
 
    Bisphosphonates inhibit both bone lesions and tumor cell burden in bone in 
experimental models of breast carcinomas. They act by decreasing the recruitment, 
proliferation and differentiation of pre-osteoclasts, their adhesion to the mineralized matrix 
and, most importantly, the resorptive activity of mature osteoclasts. They also reduce the 
release of bone derived tumor growth factors and shorten the osteoclast lifespan by 
induction of programmed cell death (Fig. 13) [54, 55].  
 
 
Figure 13. Inhibitory action of bisphosphonates in the vicious cycle of osteolytic metastasis. 
(Adapted from Rogers, T. L.) 
 
In addition, there is extensive evidence that these agents exert direct antitumor effects in 
vitro, inhibiting tumor cell adhesion, invasion, proliferation and angiogenesis, and inducing 
apoptosis. 
 
30 
 
    Because BPs home to bone very quickly due to their high affinity for hydroxyapatite, 
they are present in the skeleton for prolonged periods. 
 
    However, BPs therapy is only for palliative treatment and does not provide a life 
prolonging benefit in the majority of the patients. New therapeutics targeting osteoclast 
activities are therefore required. They could be used alone or in combination with BPs to 
treat more efficiently breast cancer patients with bone (osteolytic) metastases [56]. 
 
    Newer bone resorption inhibitors are currently in clinical development. These new 
therapeutics include OPG, anti-PTHrP antibodies, vitamin D analogues (to decrease 
PTHrP production) and RANK-Fc, a hybrid chimeric molecule that acts in an identical way 
to OPG [46, 56]. 
    The use of CATK inhibitors has been investigated as well. CATK inhibitors are 
successfully used in the treatment of bone loss associated with osteoporosis. This 
protease is also expressed by human breast cancer cells in skeletal metastases, 
suggesting that CATK inhibitors could target not only osteoclasts but also tumour cells. 
Preclinical studies show some evidence that these inhibitors, alone or in combination with 
bisphosphonates, reduce breast cancer–induced osteolysis and skeletal tumor burden in 
animals [46, 56].  
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1.4 Proton pump inhibitors 
 
    Proton pump inhibitors (PPI) and histamine 2 receptor antagonists (H2RAs) are the 
most popular acid-suppressive drugs (ASDs) available, and millions of individuals 
currently take these medications on a continuous or long-term basis. These potent drugs 
are used to treat various disorders, and indications for long-term maintenance therapy 
with this drug class continue to expand [74]. First, the H2RAs were introduced, offering 
patients the first single-agent therapy that effectively reduced gastric acid secretion. Then, 
PPI became widely available in the early 1990s, and they generally appeared to be 
superior to the H2RAs in their acid-suppressing activity, symptom control and healing [69]. 
 
    1.4.1 Mechanism of action  
 
    PPIs are a class of drugs widely used in many pathological conditions, such as 
gastroesophageal reflux, dyspepsia and peptic ulcers. Although there are several different 
molecules belonging to this class, it is known that they share many functional and 
structural properties as well as some pharmacokinetic characteristics. The mechanism of 
action of PPIs relies on their chemical activation in a significant acidic environment and 
consequent inhibition of H+/K+ATPases. Nevertheless, like any other medication, they 
also display several side effects [65, 67].  
.  
    Omeprazole was the first PPI used in clinical practice in the late 1980s. Other 
analogues such as lansoprazole, rabeprazole and esomeprazole have been developed 
since that (Fig. 14) [67].  
 
 
Figure 14. Structures of PPIs. Timoprazole, omeprazole, lansoprazole and rabeprazole are 
benzimidazole-based PPIs. Esomeprazole is an optical isomer of omeprazole (S-omeprazole). 
(Adapted from Sachs, G. et al.) 
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    PPIs are lipophilic and are inactive in the neutral environment of the bloodstream. After 
absorption, PPIs cross the plasma membrane, enter and accumulate in the secretory 
canaliculi of parietal cells, where they are protonated by acid and then converted into their 
active form, sulfenamide. The activated sulfenamide reacts covalently with the cysteine 
residues on the extracellular surface of the proton pump, inhibiting gastric acid secretion 
(Fig. 15) [67].  
 
 
Figure 15. PPIs  activation. PPIs such as omeprazole concentrate in the acidic secretory 
canaliculi of the parietal cell, where they are activated and generate a sulphenamide. The 
sulphenamide interacts covalently with the sulphydryl goups of cysteine residues in the 
extracellular domain of the ATPase thereby inhibiting its activity. (Adapted from Olbe, L. et al)  
 
    PPIs are very specific to the inhibition of gastric proton pumps because they are 
activated only in the acidic environment of the stomach, whereas they are not activated by 
the similar enzyme found in the colon and the kidney [67]. Differences in cysteine binding 
properties among the PPIs may, at least partly, underlie the differences among them in 
the duration of the inhibition of gastric acid secretion. Currently available benzimidazole-
based PPIs have similar half-lives of 1–2 h. As these agents are usually prescribed once 
daily, this means that there is effectively no circulating PPI present at the end of the 
dosing interval. A PPI with an extended half-life might have a prolonged anti-secretory 
effect with consequent therapeutic advantages [65]. 
 
    1.4.2 Adverse effects    
 
    As mentioned above, there are common adverse events that occur in 1-4% of patients. 
The most common are headache, abdominal pain, gastrointestinal alterations (nausea 
and diarrhea, for example), fatigue, community-acquired pneumonia, acute interstitial 
nephritis and allergy-related problems. However, the knowledge of the adverse events of 
newly marketed drugs is limited, and it is only after widespread clinical use that the side-
effect profile of a drug is performed more assertively. The presence of side effects on 
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proton pump inhibitors is greatest for omeprazole, since this drug has been on the market 
for a longer period [68, 70, 73]. 
    PPIs reduce gastric acidity, which is necessary to activate pepsinogen into pepsin, 
which, by its turn is important for the beginning of the digestion of dietary proteins and to 
release vitamin B12 from food. PPIs used for a short-term may minimally reduce the 
absorption of protein-bound vitamin B12. Elderly patients who already have gastric 
atrophy may present lower levels of vitamin B12 in serum with long term PPIs used. 
However, studies have shown that PPIs used for a long-term in younger patients do not 
reduce serum vitamin B12 concentrations. In patients long-term treated with high dose of 
PPIs duodenal absorption of organic and non-organic iron may be reduced. Nevertheless, 
this effect is small, and PPIs are not associated with an increased risk of latent iron 
deficiency or iron deficiency [68, 70, 73]. 
 
    For the proton pump inhibitors omeprazole, lansoprazole, pantoprazole and 
esomeprazole, certain hepatic isoenzyme pathways, notably cytochrome P450 
(CYP2C19), have an important role in the drug metabolism. In particular, among patients 
who are genotypically rapid, or extensive, metabolizers, proton pump inhibitors with 
significant CYP2C19 metabolism tend to yield lower plasma levels and, thus, have low 
efficacy. The contribution of the CYP2C19 pathway varies in the metabolism of the 
different proton pump inhibitors [69]. 
 
    1.4.3 PPI’s versus H2RAs 
 
    Despite the efficiency of the action of the H2RAs, there were patients whose acid-
related disorders failed to respond to or required very high doses of these drugs. 
Furthermore, the phenomenon of H2RA tolerance was recognized, with implications on 
possible failures of chronic/maintenance H2RA therapy. PPIs were subsequently 
developed, and, in most cases, have been found to be superior to H2RAs in their acid 
suppressing ability. They also relieve oesophagitis symptoms and heal erosions more 
effectively than H2RAs. In contrast to H2RAs or anticholinergic agents, which only 
partially inhibit histamine-, gastrin- or acetylcholine- stimulated acid secretion, PPIs inhibit 
acid secretion in response to all stimulatory agents (Fig. 16). Consequently, PPIs are 
exceptionally effective for the control of acid production. Moreover, PPIs elevate pH above 
3-4 4 for longer time periods than do H2RAs[69]. 
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Figure 16. Gastric acid secretion by parietal cell. Gastric acid secretion is a process regulated 
by three types of receptors on the parietal cell (histamine, gastrin and acetylcholine). Activation of 
these receptors leads to activation of the gastric acid proton pump, H+K+-ATPase, which regulates 
acid transport and is the final common pathway to acid secretion for these three receptors. In 
contrast to H2RAs which only partially block these receptors, PPIs directly block the action of 
H+K+-ATPase, suppressing gastric acid secretion, regardless of the stimulus. (Adapted from Olbe, 
L. et al.) 
 
    1.4.4 Secondary effects of PPI in bone metabolism 
 
    Long-term PPI therapy and its attendant potent acid suppressive properties have 
generated great concern regarding to the potential effects on calcium absorption and bone 
metabolism. Several epidemiological studies have suggested an association between PPI 
use and the risk of fractures of the hip, or other sites, including spine, wrists and forearms.  
    Some potential mechanisms by which PPI therapy may lead to fractures have been 
identified. First, the small intestine’s ability to absorb ingested calcium depends on pH. 
Without an acidic environment in the gastrointestinal tract, calcium may be retained in the 
food matrix preventing absorption. Second, impaired calcium absorption may lead to 
compensatory secondary hyperparathyroidism. Secondary hyperparathyroidism refers to 
the increase in circulating levels of parathyroid hormone, which, in an attempt to rectify the 
deficit in calcium absorption, increase the rate of osteoclastic activity [66, 72]. Finally, PPI 
may directly interfere with osteoclasts activity [74]. Studies have shown that omeprazole 
inhibits bone resorption in vitro and in vivo in humans by inhibiting osteoclastic vacuolar 
H+ ATPase activity. A reduced bone resorption should lead to increases in bone density, 
however, bone resorption is necessary for the normal bone development, replacing old 
bone and repairing microfractures. Thus, a decrease in osteoclast activity can affect bone 
structure and, thus, predispose patients to fractures [66, 70, 72, 74].  
35 
 
    Taken together, these studies are limited by a low magnitude of association and 
inability to assess potential confounding factors [79]. Despite all these reservations, it 
seems likely that PPI may affect significantly bone metabolism, particularly in some 
vulnerable individuals, such as postmenopausal women, where PPI use contributes to an 
increased risk of fractures at various sites, in a manner related to the dose and duration of 
exposure to the drug [66, 70, 74, 80].  
 
    In this context, since in the resorption process osteoclasts solubilize the bone mineral 
phase through the secretion of acid to the resorption lacuna by proton pumps of the 
vacuolar type, V-ATPases, PPIs appear as potentially pharmacological modulators of 
osteoclastic activity, particularly in pathological situations characterized by hiperactivation 
of osteoclasts such as osteolytic metastases associated with breast cancer.  
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2. Materials and methods  
 
    2.1 Cell Cultures 
 
    2.1.1 Isolation of Peripheral blood mononuclear cells (PBMC) 
 
    The cells were isolated from blood of male healthy donors with ages between 25 and 
35 years old. The blood was diluted with PBS (phosphatase buffer solution) supplemented 
with 2 mM EDTA (1:2) and applied on top of 4ml of Ficoll-PaqueTM PREMIUM (GE 
Healthcare Bioscience). After centrifugation at 400 g for 30 minutes at room temperature, 
PBMC were collected and washed twice with PBS supplemented with 2 mM EDTA with 
centrifugations at 300 g for 10 minutes at 4ºC in each. PBMC were seeded at 
1.5x106cells/cm2. 
 
    2.1.2 Breast cancer cell lines culture (T47D and SK-BR-3) 
 
    Human breast cancer cell lines, estrogen-receptor positive T47D and estrogen-negative 
SK-BR-3, were maintained in α-Minimal Essential Medium (α-MEM) supplemented with 
10% (v/v) fetal bovine serum, 100 IU/mL penicillin, 2.5 µg/mL streptomycin, 2.5 µg/mL 
amphotericin B and 50 µg/mL ascorbic acid. Cultures were performed at 37ºC in a 5% 
CO2 humidified atmosphere. At about 70-80% confluence, cells were detached with 0.05% 
trypsin and 0.5 mM EDTA, and separately seeded at 104cells/cm2.     
 
    Cell cultures were maintained in α-MEM supplemented with 10% (v/v) fetal bovine 
serum, 100 IU/mL penicillin, 2.5 µg/mL streptomycin, 2.5 µg/mL amphotericin B and 50 
µg/mL ascorbic acid. Cultures were treated with different PPI (omeprazole, esomeprazole 
and lansoprazole), at a concentration range of 10-9-10-3 M. Culture medium was changed 
once a week and PPI were renewed at each medium change. Cell cultures were 
maintained for 21 days in a 5% CO2 humidified atmosphere at 37ºC. 
 
    Cultures were assessed for cellular viability/ proliferation and apoptosis.  
 
    2.1.3 Co-culture of SK-BR-3 and T47D and PBMC 
 
    SK-BR-3 and T47D cell lines were separately seeded at 102 cells/cm2 and 104cells/cm2, 
respectively. Cultures were incubated for 24h at 37ºC in α-MEM supplemented with 10% 
(v/v) fetal bovine serum, 100 IU/mL penicillin, 2.5 µg/mL streptomycin, 2.5 µg/mL 
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amphotericin B and 50 µg/mL ascorbic acid. After that time, PMBC were added at 
1.5x106cells/cm2. 
 
    Cell cultures were maintained in α-MEM supplemented with 30% (v/v) human serum 
(from the same donor where PBMC were obtained), 100 IU/mL penicillin, 2.5 µg/mL 
streptomycin, 2.5 µg/mL amphotericin B and 2 mM L-glutamine. Cultures were treated 
with different PPI (omeprazole, esomeprazole and lansoprazole), at a concentration range 
of 10-7-10-3 M. Culture medium was changed once a week and PPI were renewed at each 
medium change. Cell cultures were maintained for 21 days in a 5% CO2 humidified 
atmosphere at 37ºC.  
 
    Cultures were assessed for total protein content, TRAP activity, number of TRAP 
positive cells, presence of multinucleated cells with actin rings and expressing VNR and 
CTR by confocal laser scanning microscopy (CLSM) and calcium phosphate resorbing 
ability. In order to assess the intracellular mechanisms involved, when indicated, the 
medium was also supplemented with several signalling pathway inhibitors, namely, 1µM 
U0126 (MAPK/ERK pathway inhibitor), 10µM PDTC (NF-kB pathway inhibitor), 5µM GO 
6983 (PKC pathway inhibitor) and 10µM SP (JNK pathway inhibitor).  
 
    2.1.4 Human fetal osteoblastic cell line (hFOB) culture 
 
    The hFOB cells were cultured in Dulbecco’s Modified Eagle’s Medium/HAM’s Nutrient 
Mixture F12 (DMEM/F12) supplemented with 10% (v/v) fetal bovine serum, 100 IU/mL 
penicillin, 2.5 µg/mL streptomycin, 2.5 µg/mL amphotericin B, 50 µg/mL ascorbic acid and 
0,6% gentamicin. Cultures were performed at 37ºC in a 5% CO2 humidified atmosphere. 
At about 70-80% confluence, cells were detached with 0.05% trypsin and 0.5 mM EDTA, 
and seeded at 104cells/cm2.  
 
    Cell cultures were maintained in DMEM/F12 supplemented with 10% (v/v) fetal bovine 
serum, 100 IU/mL penicillin, 2.5 µg/mL streptomycin, 2.5 µg/mL amphotericin B, 50 µg/mL 
ascorbic acid and 0,6% gentamicin, in absence and presence of 1% dexamethasone. 
Cultures were treated with different PPI at a concentration range of 10-7-10-3 M. Culture 
medium was changed once a week and PPI were renewed at each medium change. Cell 
cultures were maintained for 21 days in a 5% CO2 humidified atmosphere at 37ºC. 
 
    Cultures were assessed for cellular viability/ proliferation, total protein content, ALP 
activity and histochemical staining and visualized by CLSM. It was also carried out a 
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characterization of the intracellular mechanisms involved, for that, cells were seeded at 
104cells/cm2 and maintained in DMEM/F12 as described above. When indicated, the 
medium was also supplemented with several signalling pathway inhibitors, namely, 1µM 
U0126 (MAPK/ERK pathway inhibitor), 10µM PDTC (NF-kB pathway inhibitor), 5µM GO 
6983 (PKC pathway inhibitor) and 10µM SP (JNK pathway inhibitor).  
 
    2.2 Characterization of cell cultures 
 
    2.2.1 Total protein quantification 
 
    Cellular protein content was determined by Bradford’s method. Cell cultures were 
washed twice with PBS and solubilized with 0.1 M NaOH. Samples were treated with 
Coomassie® Protein Assay Reagent (Fluka) and incubated for 2 minutes at room 
temperature. The absorbance was quantified at 595 nm in an ELISA plate reader (Sinergy 
HT, Bioteck). Results were expressed as mg/mL.      
  
    2.2.2 TRAP activity quantification 
 
    TRAP activity was assessed by para-nitrophenilphosphate (pNPP) hydrolysis method. 
Cell cultures were washed twice with PBS and solubilized with 0.1% (V/V) Triton X-100. 
Samples were incubated for 1 hour at 37ºC with 10 mM pNPP prepared in 0.04 M tartaric 
acid and 0.09 M citrate at pH 4.8. After incubation, the reaction was stopped with 5 M 
NaOH and the absorbance was measured at 400 nm in an ELISA plate reader (Synergy 
HT, Bioteck). Results were normalized with total protein content and expressed as 
nmol/min/µgprotein. 
    
    2.2.3 Histochemical staining of TRAP 
 
    At days 14 and 21, cell cultures were washed twice with PBS and fixed with 3.7% (v/v) 
formaldehyde for 15 minutes at room temperature. After new wash with PBS, cells were 
stained for TRAP with Acid Phosphatase Leukocyte (TRAP) kit (SIGMA), according to 
manufacturer’s instructions. Shortly, cells were incubated with naphtol AS-BI 0.12 mg/mL, 
in the presence of 6.76 nM tartrate and 0.14 mg/mL Fast Garnet GBC, for 1 hour at 37ºC 
in the dark. After incubation, cell layers were washed, stained with hematoxilin and 
visualized by light microscopy. TRAP positive multinucleated cells (purple/dark red) were 
counted.  
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    2.2.4 ALP activity quantification 
 
    ALP activity was also determined by the pNPP hydrolysis method used to TRAP activity 
quantification. Here, after solubilization with 0.1% (V/V) Triton X-100, samples were 
incubated with 10 mM pNPP in a 0.15 M bicarbonate buffer in 2.5 mM MgCl2 at pH 10. 
The procedure was the same as described for TRAP activity.  
 
    2.2.5 Histochemical staining of ALP 
 
    Cell cultures were washed twice with PBS and fixed with 1.5% glutaraldehyde in 
cacodylate buffer, for 10 minutes at room temperature. After fixation, cells were incubated 
with 30 mg/mL phosphatase naphthyl in 0.1 M Tris buffer at pH 10, in the presence of 30 
mg/mL Fast Blue RR Salt, for 1 hour at 37ºC, in the dark. After incubation, cell layers were 
washed and visualized by light microscopy.   
 
    2.2.6 Cellular proliferation/viability 
 
    The celular proliferation/viability assessment was performed by MTT (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay.  Cell cultures were 
incubated with 5 mg/mL MTT, for 4 hours at 37ºC. After incubation, the medium was 
removed and 100 µL dimethyl sulfoxide (DMSO) was added. The absorbance was 
quantified at 550nm in an ELISA plate reader (Synergy HT, Bioteck). 
 
    2.2.7 Immunofluorescence staining and visualization by CLSM 
 
    Cell cultures were washed twice with PBS and fixed with 3.7% (v/v) paraformaldehyde, 
for 15 minutes at room temperature. After fixation, cells were washed again with PBS and 
permeabilized with 0.1% (V/V) Triton X-100 for 5 minutes. Cultures were then stained for 
F-actin with 5 U/mL Alexa Fluor® 647-Phalloidin (Invitrogen), for nucleus with 500 nM 
propidium iodide, and for vitronectin receptors (VNR) and calcitonin receptors (CTR) with 
50 µg/mL mouse IgGs anti-VNR and IgGs anti-CTR (R&D Systems), respectively. Anti-
VNR and anti-CTR detection was performed with 2 µg/mL Alexa Fluor® 488 anti-mouse 
IgGs (Invitrogen). Cultures were visualized by CLSM. 
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    2.2.8 Apoptosis quantification 
 
    Apoptosis was analyzed through caspase 3 activity quantification. For that, breast 
cancer cell cultures were washed twice with PBS and assessed for caspase 3 activity with 
EnzCheck® Caspase 3 Assay Kit # 2 (Molecular Probes), according to manufacturer’s 
instructions. The fluorescence was measured at 486/520 nm (excitation/emission) in an 
ELISA plate reader (Synergy HT, Bioteck).  
 
    2.2.9 Calcium phosphate resorbing ability 
 
   Co-cultures of SK-BR-3 and T47D and PBMC were performed on calcium phosphate 
coated culture plates (BD BioCoat™ Osteologic™ Bone Cell Culture Plates, BD 
Biosciences), for 21 days. After that period, cells were bleached with 6% NaOCl and 5.2% 
NaCl, and the remaining calcium phosphate layers were visualized by phase contrast light 
microscopy (Nikon TMS phase contrast microscope). Resorption lacunae were identified 
and total resorbed area was quantified with ImageJ 1.41 software. Results were 
presented as a % of resorbed area. 
 
    2.2.10 Statistical analysis 
 
    Data presented in this work are the means of separate experiments. Three replicas of 
each condition were made for each experiment and data are expressed as the mean ± 
standard deviation. Data were evaluated using a two-way analysis of variance (ANOVA) 
and no significant differences in the pattern of the cell behavior were observed. Statistical 
differences found between control and experimental conditions were determined by 
Bonferroni’s method. For values of p ≤ 0.05, differences were considered statistical 
significant. 
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3. Results 
                                  
    3.1 Assessment of the effects of different PPI in cultures of SK-BR-3 and T47D   
 
    In the first part of this work, it was pretended to evaluate the effects of PPI in cultures of 
SK-BR-3 and T47D. Each culture was treated with different concentrations of omeprazole, 
esomeprazole and lansoprazole, and maintained for 21 days. Samples were assessed at 
days 7, 14 and 21.  
 
    3.1.1 Characterization of SK-BR-3 cultures 
    3.1.1.1 Cellular proliferation/viability 
     
 
 
Figure 17. Cellular proliferation/viability of SK-BR-3 cultures treated with different concentrations of 
omeprazole, esomeprazole and lansoprazole. 
* 
Significantly different from the control.  
 
    In general, SK-BR-3 cell cultures maintained a cell proliferation/viability identical to 
negative control for the lowest concentrations of each PPI. However, with the increase of 
PPI concentrations, cell proliferation/viability started to decrease. This dose-dependent 
decrease was seen for the three PPI starting from the concentration 10-5 M, with a 
decrease of about 18.79%, 21.13% and 3.64% for omeprazole, esomeprazole and 
lansoprazole, respectively.  
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    3.1.1.2 Apoptosis quantification 
      
 
 
Figure 18. Caspase-3 activity of SK-BR-3 cultures treated with different concentrations of 
omeprazole, esomeprazole and lansoprazole. 
*
 Significantly different from the control.  
 
    Concentrations up to 10-5 M did not cause any significant effect on caspase-3 activity of 
SK-BR-3 cultures. However, cellular response increased significantly with the highest 
tested concentration of omeprazole and esomeprazole. Compared to the control, at day 
21 the increase was about 85.20% and 58%, in the case of omeprazole and 
esomeprazole, respectively. In the presence of lansoprazole, caspase activity was not 
significantly affected by the tested concentrations. 
 
    3.1.2 Characterization of T47D cultures 
    3.1.2.1 Cellular proliferation/viability 
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Figure 19. Cellular proliferation/viability of T47D cultures treated with different concentrations of 
omeprazole, esomeprazole and lansoprazole. 
*
 Significantly different from the control.  
 
    Cell proliferation/viability was higher for T47D cultures than for SK-BR-3 cultures. In 
general, T47D cultures maintained a cellular proliferation/viability identical to negative 
control for the lowest concentrations of each PPI. However, proliferation/viability started to 
decrease with the increase of PPI concentration starting from 10-4 M omeprazole and 
esomeprazole, and 10-5 M lansoprazole.  The decrease was about 53.80%, 30.75% and 
27.36%, respectively. 
 
    3.1.2.2 Apoptosis quantification 
      
 
 
Figure 20. Caspase-3 activity of T47D cultures treated with different concentrations of omeprazole, 
esomeprazole and lansoprazole. 
* 
Significantly different from the control.  
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    T47D cultures presented lower caspase-3 activity values than those obtained in SK-BR-
3 cultures. In general, caspase-3 activity was not affected by the presence of neither 
omeprazole nor esomeprazole, presenting similar values to the negative control at all 
tested concentrations. However, caspase activity increased in the presence of the highest 
concentration of lansoprazole (10-5 M), with an increase of about 50.80% at day 21. 
 
    3.2 Assessment of the osteoclastogenic effects of different PPI in co-cultures of 
PBMC and breast cancer cell lines 
 
    In the second part of this work, it was pretended to evaluate the effects of PPI in co-
cultures of PBMC and SK-BR-3 or T47D. SK-BR-3 and T47D cells were seeded at 
different densities, 102 cells/cm2 and 104 cells/cm2, respectively, based on previous 
studies (data not shown). Cultures were treated with different concentrations of 
omeprazole, esomeprazole and lansoprazole, and maintained for 21 days. Samples were 
assessed at days 7, 14 and 21.  
 
    3.2.1 Characterization of PBMC + SK-BR-3 co-cultures 
 
    3.2.1.1 TRAP activity 
      
 
 
Figure 21. TRAP activity on PBMC + SK-BR-3 co-cultures treated with different concentrations of 
omeprazole, esomeprazole and lansoprazole. 
* 
Significantly different from the control.  
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    As observed in Figure 21, TRAP activity of PBMC + SK-BR-3 co-cultures decreased 
with the increase of each PPI concentration. Among the three tested PPI, the one that 
induced a more significant dose-dependent decrease in TRAP activity was omeprazole, 
whereas esomeprazole was the one that affected the least. Compared to the control, the 
effects became statistically significant for the concentration of 10-7 M of omeprazole 
(~15.55%), and 10-6 M of esomeprazole (~24.40%) and lansoprazole (~34.04%). Co-
cultures displayed null levels of activity for the highest tested concentrations of 
omeprazole and lansoprazole.  
 
    3.2.1.2 Histochemical staining of TRAP  
        
 
 
Figure 22. Presence of TRAP+ multinucleated cells on PBMC + SK-BR-3 co-cultures treated with 
different concentrations of omeprazole, esomeprazole and lansoprazole. 
* 
Significantly different 
from the control. 
 
    The results of histochemical staining of TRAP (Fig. 22) were consistent with those 
obtained for TRAP activity. The number of positive TRAP multinucleated cells decreased 
with the increase of each PPI concentration, particularly in the case of omeprazole and 
lansoprazole. 
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    3.2.1.3 Calcium phosphatase resorbing ability 
  
                                                      
Figure 23. Visualization of calcium phosphatase resorbed area of PBMC + SK-BR-3 co-cultures 
treated with 10
-6
 M omeprazole, esomeprazole and lansoprazole, by light microscopy. White bars 
represent 600 µm. 
 
Figure 24. Calcium phosphatase resorbed area of PBMC + SK-BR-3 co-cultures treated with 10
-6
 
M omeprazole, esomeprazole and lansoprazole. 
*
Significantly different from the control.  
 
    Visualization of calcium phosphatase resorbed area by light microscopy showed a 
decrease in calcium phosphatase resorbing ability in the presence of the three PPI. The 
co-culture that presented the lowest area of resorption was the one that was treated with 
10-6 M omeprazole, with a maximal inhibition of 41% compared to control. In the presence 
of esomeprazole and lansoprazole the inhibition was about 27% and 34%, respectively.   
 
    3.2.1.5 Characterization of the intracellular mechanisms involved in the cellular 
response 
 
    Following the assessment of the osteoclastogenic effects of PPI in co-cultures of PBMC 
and SK-BR-3, it was also carried out a characterization of the intracellular mechanisms 
0,00 
10,00 
20,00 
30,00 
40,00 
50,00 
60,00 
70,00 
%
 R
e
so
rp
ti
o
n
 A
re
a 
PBMC + SK-BR-3 
Control Omeprazole 
Esomeprazole Lansoprazole 
Negative control                 Omeprazole (10
-6
 M) 
 
 
 
 
Esomeprazole (10
-6
 M)       Lansoprazole (10
-6
 M) 
* * * 
Eso eprazole (10
-6
 )      Lansoprazole (10
-6
 ) 
47 
 
involved in this process. For that, co-cultures were maintained for 21 days in the absence 
or presence of 10-6 M (the lowest common concentration that elicited a significant anti-
osteoclastogenic effect either in TRAP activity and staining) of each PPI and treated with 
intracellular signaling pathway inhibitors: 1µM U0126 (MAPK/ERK inhibitor); 10µM PDTC 
(NF-kB inhibitor); 5µM GO 6983 (PKC inhibitor) and 10µM SP 600125 (JNK inhibitor). 
Samples were assessed at days 7, 14 and 21. 
 
    3.2.1.5.1 TRAP activity 
             
 
             
Figure 25. TRAP activity on PBMC + SK-BR-3 co-cultures treated with 10
-6
 M omeprazole, 10
-6
 M 
esomeprazole and 10
-6
 M lansoprazole and supplemented with different intracellular signalling 
pathway inhibitors. 
* 
Significantly different from the control. 
 
    TRAP activity of untreated PBMC + SK-BR-3 co-cultures decreased in the presence of 
all the inhibitors tested, with the one exception being GO6983, which did not significantly 
affect the cellular behavior. Co-cultures treated with omeprazole displayed a similar 
pattern of cell response. In the presence of esomeprazole, only PDTC negatively affected 
TRAP activity, while the remaining inhibitors did not affect cellular response. Finally, in the 
presence of lansoprazole, U0126 and PDTC inhibited TRAP activity similarly to the 
control, whereas co-cultures supplemented with GO6983 displayed a significantly higher 
decrease on cell response. On the other hand, in the presence of SP600125 TRAP 
activity was less affected. 
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    The results of histochemical staining of TRAP were consistent with those obtained for 
TRAP activity, showing more evidently that GO6983 was the inhibitor that less affected 
the cultures, except for the cultures treated with lansoprazole (data not shown). 
                                
    3.2.2 Characterization of PBMC + T47D co-cultures 
    3.2.2.1 TRAP activity 
       
 
 
Figure 26. TRAP activity of PBMC + T47D co-cultures treated with different concentrations of 
omeprazole, esomeprazole and lansoprazole. 
*
 Significantly different from the control.  
 
    PBMC + T47D co-cultures presented levels of TRAP activity higher than those obtained 
in PBMC + SK-BR-3 co-cultures. TRAP activity decreased with the increase of each PPI 
concentration. This dose-dependent inhibition was higher in the presence of omeprazole 
and lansoprazole. Compared to the control, the effects became statistically significant for 
the concentration of 10-7 M omeprazole (30.93%) 10-5 M of esomeprazole (16.87%) and 
10-7 M of lansoprazole (34%). Again, co-cultures treated with the highest concentrations of 
omeprazole and lansoprazole displayed null levels of TRAP activity. 
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    3.2.2.2 Histochemical staining of TRAP 
       
 
 
Figure 27. Presence of TRAP+ multinucleated cells on PBMC + T47D co-cultures treated with 
different concentrations of omeprazole, esomeprazole and lansoprazole. 
*
Significantly different 
from the control.   
 
    PBMC + T47D co-cultures showed a higher presence of TRAP multinucleated cells 
than PBMC + SK-BR-3 co-cultures. As observed for TRAP activity, the number of TRAP+ 
multinucleated cells decreased with the increase of each PPI concentration, particularly in 
the presence of omeprazole and lansoprazole. 
 
    3.2.2.3 Calcium phosphatase resorbing ability 
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Figure 28. Visualization of calcium phosphatase resorbed area of PBMC + T47D co-cultures 
treated with 10
-7
 M omeprazole, 10
-5
 M esomeprazole and 10
-7
M lansoprazole, by light microscopy. 
White bars represent 600µm. 
 
Figure 29. Resorbed area of PBMC + T47D co-cultures treated with 10
-7
 M omeprazole, 10
-5
 M 
esomeprazole and 10
-7
 M lansoprazole. 
*
Significantly different from the control.  
 
    Visualization of calcium phosphatase resorbed area by light microscopy showed a 
decrease in calcium phosphatase resorbing ability in the presence of the three PPI. The 
co-culture that presented the lowest area of resorption was the one that was treated with 
10-7 M omeprazole, with a maximal inhibition of 44% compared to the control. In the 
presence of esomeprazole and lansoprazole the inhibition was about 23% and 35%, 
respectively.  Globally, PBMC + T47D co-cultures presented a higher resorbing ability 
than PBMC + SK-BR-3 co-cultures (53% versus 30%).  
 
    3.2.2.4 Visualization of cells with actin rings and expression of VNR and CTR 
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Figure 30. Visualization of cells with actin rings and expression of VNR and CTR of PBMC + T47D 
co-cultures in absence and presence of 10
-6
 M omeprazole, by CLSM. Cells were stained blue for 
actin and green for VNR and CTR. White bars represent 150µm.  
 
    Visualization of PBMC + T47D co-cultures by CSLM revealed the presence of 
osteoclastic cells in all analysed conditions. The results were somehow in line with the 
data obtained from the previous analysis. That means, co-cultures treated with 10-6 M 
omeprazole showed a decrease in osteoclastic cells compared to the negative control. 
 
    3.2.2.5 Characterization of the intracellular mechanisms involved in the cellular 
response 
 
    Characterization of the intracellular mechanisms involved in osteoclastogenesis was 
also performed in PBMC + T47D co-cultures. For that, co-cultures were maintained for 21 
days in the absence and presence of 10-7 M omeprazole, 10-5 M esomeprazole and 10-7 M 
lansoprazole (the lowest concentration of each PPI that elicited a significant anti-
osteoclastogenic effect) and treated with intracellular signalling pathway inhibitors: 1µM 
U0126 (MAPK/ERK inhibitor); 10µM PDTC (NF-kB inhibitor); 5µM GO 6983 (PKC 
inhibitor) and 10µM SP 600125 (JNK inhibitor). Samples were assessed at days 7, 14 and 
21. 
 
    3.2.2.5.1 TRAP activity 
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Figure 31. TRAP activity on PBMC + T47D co-cultures treated with 10
-7
 M omeprazole, 10
-5 
M 
esomeprazole and 10
-7
 M lansoprazole and supplemented with different intracellular signalling 
pathway inhibitors. 
* 
Significantly different from the control.  
 
    TRAP activity of untreated and treated PBMC + T47D co-cultures decreased in the 
presence of all the tested inhibitors. In co-cultures treated with omeprazole and 
esomeprazole, with exception of U0126 that equally affected TRAP activity, the presence 
of all the inhibitors induced a less significant inhibition than in untreated cultures. In the 
presence of lansoprazole, TRAP activity decreases were similar to those seen on 
untreated cultures for those supplemented with U0126, PDTC and GO6983, whereas 
SP600125 supplemented cultures were less affected. 
    The results of histochemical staining of TRAP were consistent with those obtained for 
TRAP activity. (data not shown) 
 
    3.3 Assessment of the effects of different PPI in cultures of hFOB 
 
    Finally, in the last part of this work, the aim was to evaluate the effects of PPI in 
cultures of hFOB. Cultures were performed in the absence and presence of the 
osteogenic inducer dexamethasone (DEX) and supplemented with different 
concentrations of omeprazole, esomeprazole and lansoprazole. Cell cultures were 
maintained for 21 days and samples were assessed at days 7, 14 and 21. 
 
    3.3.1 Characterization of hFOB cultures (-DEX) 
    3.3.1.1 Cellular proliferation/viability 
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Figure 32. Cellular proliferation/viability of hFOB cultures treated with different concentrations of 
omeprazole, esomeprazole and lansoprazole, in absence of DEX. 
* 
Significantly different from the 
control.  
 
    Cellular proliferation/viability of hFOB cultures, maintained in the absence of DEX, 
decreased with the increase of each PPI concentration. This dose-dependent inhibition 
was higher in the presence of omeprazole and lansoprazole, with null levels of cellular 
proliferation/viability for the highest concentration of lansoprazole (10-3 M). The inhibition 
became statistically significant in the presence of 10-6 M omeprazole and lansoprazole 
and 10-5 M esomeprazole, with a corresponding inhibition of about 17.78%, 31.30% and 
16.69%. 
 
    3.3.1.2 ALP activity 
       
 
 
Figure 33. ALP activity of hFOB cultures treated with different concentrations of omeprazole, 
esomeprazole and lansoprazole, in absence of DEX. 
* 
Significantly different from the control. 
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    As observed for cellular proliferation/viability, ALP activity of hFOB cultures, maintained 
in the absence of DEX, decreased with the increase of PPI concentration, particularly in 
the presence of omeprazole and lansoprazole, with null levels of activity for the highest 
concentration (10-3 M). The inhibition became statistically significant in the presence of 10-
6 M omeprazole (39.46%), 10-6 M esomeprazole (8.16%) and 10-6 M lansoprazole 
(25.85%). 
 
    3.3.1.3 Histochemical staining of ALP 
       
        
Figure 34. Histochemical staining of ALP in hFOB cultures treated with 10
-6
 M omeprazole, 
esomeprazole and lansoprazole, in absence of DEX. White bars represent 200µm.  
 
    Visualization of histochemical staining of ALP revealed a cellular behavior consistent 
with the data obtained from ALP activity analysis. Cultures treated with 10-6 M omeprazole 
and lansoprazole displayed a significant decrease in ALP expression, while the same 
concentration of esomeprazole did not  have a so sharp effect in the cellular response. 
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   3.3.2 Characterization of hFOB cultures (+DEX) 
    3.3.2.1 Cellular proliferation/viability 
        
 
 
Figure 35. Cellular proliferation/viability of hFOB cultures treated with different concentrations of 
omeprazole, esomeprazole and lansoprazole, in the presence of DEX. 
* 
Significantly different from 
the control.  
 
    Cellular proliferation/viability of hFOB cultures, in presence of DEX, decreased with the 
increase of each PPI concentration. This dose-dependent inhibition was higher in the 
presence of omeprazole and lansoprazole. The inhibition became statistically significant in 
the presence of 10-7 M omeprazole, 10-5 M esomeprazole and 10-4 M lansoprazole, with a 
corresponding inhibition of about 13.92%, 12.66% and 31.65%. 
 
    3.3.2.2 ALP activity 
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Figure 36. ALP activity of hFOB cultures treated with different concentrations of omeprazole, 
esomeprazole and lansoprazole, in the presence of DEX. 
*
 Significantly different from the control. 
 
    ALP activity of hFOB cultures, in the presence of DEX, decreased with the increase of 
each PPI concentration, particularly in the presence of omeprazole and lansoprazole.  The 
inhibition became statistically significant starting from the concentration 10-6 M, with a 
decrease of about 21.07%, 10.98% and 13.95% for omeprazole, esomeprazole and 
lansoprazole, respectively. Once again, co-cultures treated with the highest 
concentrations of omeprazole and lansoprazole displayed null levels of TRAP activity. 
 
    3.3.2.3 Histochemical staining of ALP 
     
      
Figure 37. Histochemical staining of ALP in hFOB cultures treated with 10
-6
 M omeprazole, 
esomeprazole and lansoprazole, in the presence of DEX. White bars represent 200µm.  
 
    The results of histochemical staining of ALP were consistent with those obtained in ALP 
activity analysis, showing that cultures treated with omeprazole and lansoprazole had less 
expression of ALP. 
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3.3.2.4 Visualization of hFOB cultures by CLSM 
   
   
Figure 38. Visualization of hFOB cultures treated with 10
-6
 M omeprazole, esomeprazole and 
lansoprazole, in the presence of DEX, by CLSM. Cells were stained green for actin and red for 
nuclei. White bars represent 60µm. 
 
    Visualization of hFOB cultures by CLSM revealed the presence of osteoblastic cells in 
all tested conditions. Results were consistent with the data obtained from the previous 
analysis, that is, cultures treated with omeprazole and lansoprazole showed a more 
significant decrease in the amount of osteoblastic cells compared to the negative control. 
 
    3.3.3 Characterization of the intracellular effects involved in the observed cellular 
response  
 
    Following the assessment of the effects of PPI in cultures of hFOB, it was also carried 
out a characterization of the intracellular mechanisms involved in the observed cellular 
behavior. For that, cultures were maintained for 21 days in the absence and presence of 
10-6 M of each PPI and treated with intracellular signalling pathway inhibitors: 1µM U0126 
(MAPK/ERK inhibitor); 10µM PDTC (NF-kB inhibitor); 5µM GO 6983 (PKC inhibitor) and 
10µM SP 600125 (JNK inhibitor). Samples were assessed at days 7, 14 and 21. 
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   3.3.3.1 Cellular proliferation/viability of hFOB cultures (-DEX)  
             
 
             
Figure 39. Cellular proliferation/viability of hFOB cultures treated with 10
-6
 M omeprazole, 10
-6
 M 
esomeprazole and 10
-6
 M lansoprazole, in absence of DEX, and supplemented with different 
intracellular signalling pathway inhibitors. 
*
Significantly different from the control.  
 
    Cellular proliferation/viability of untreated hFOB cultures decreased in the presence of 
all the inhibitors. In cultures treated with omeprazole, U0126 and PDTC induced a less 
significant inhibition of cellular proliferation/viability than in control, whereas cultures 
supplemented with GO6983 and SP600125 displayed a higher decrease. In the presence 
of esomeprazole, with exception of U0126 that did not affect cultures, all the inhibitors 
induced similar changes to those seen for cultures treated with omeprazole. Finally, in the 
presence of lansoprazole, cultures supplemented with U0126 and GO6983 displayed 
cellular proliferation/viability decreases similar to those obtained in control, while PDTC 
induced a higher decrease. On the other hand, in the presence of SP600125 cultures 
were less affected.  
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    3.3.3.2 ALP activity of hFOB cultures (-DEX) 
       
 
      
Figure 40. ALP activity of hFOB cultures treated with 10
-6
 M omeprazole, 10
-6
 M esomeprazole and 
10
-6
 M lansoprazole, in absence of DEX, and supplemented with different intracellular signalling 
pathway inhibitors. 
*
Significantly different from the control.  
 
    ALP activity of control cultures decreased in the presence of all the inhibitors. In the 
presence of omeprazole, U0126 and PDTC did not affect ALP activity, while cultures 
supplemented with GO6983 showed a lower decrease compared to the control. The 
presence of SP600125 induced a higher decrease. Cultures treated with esomeprazole 
displayed a less significant decrease for inhibitors U0126 and PDTC. On the other hand, 
the presence of GO6983 and SP600125 induced a higher decrease in ALP activity. In 
contrast, in the presence of lansoprazole, GO6983 and SP600125 induced an increase in 
ALP activity. Cultures supplemented with U0126 showed a higher decrease compared to 
the control and those supplemented with PDTC a lower one.   
 
    3.3.3.3 Cellular proliferation/viability of hFOB cultures (+DEX) 
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Figure 41. Cellular proliferation/viability of hFOB cultures treated with 10
-6
 M omeprazole, 10
-6
 M 
esomeprazole and 10
-6
 M lansoprazole, in presence of DEX, and supplemented with different 
intracellular signalling pathway inhibitors. 
*
Significantly different from the control.  
 
    Cellular proliferation/viability of untreated hFOB cultures decreased in the presence of 
all the inhibitors tested with exception of U0126 which did not affect the cultures.  In 
cultures treated with omeprazole, only GO6983 and SP600125 negatively affected cellular 
proliferation/viability, inducing a higher decrease compared to the control. In the presence 
of esomeprazole, cultures supplemented with U0126 were negatively affected. The 
presence of PDTC induced a lower decrease of cellular proliferation/viability to that on 
control cultures, whereas GO6983 and SP600125 induced similar changes. Finally, in the 
presence of lansoprazole, PDTC and SP600125 induced similar changes to those seen 
on control, while GO6983 induced a higher decrease. Again, cultures supplemented with 
U0126 were negatively affected.     
 
    3.3.3.4 ALP activity of hFOB cultures (+DEX) 
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Figure 42. ALP activity of hFOB cultures treated with 10
-6
 M omeprazole, 10
-6
 M esomeprazole and 
10
-6
 M lansoprazole, in presence of DEX, supplemented with different intracellular signalling 
pathway inhibitors. 
*
Significantly different from the control.  
 
    ALP activity of untreated hFOB cultures decreased in the presence of all the inhibitors. 
In cultures treated with omeprazole and esomeprazole, U0126 and GO6983 induced a 
lower decrease in ALP activity compared to the control, while SP600125 induced a higher 
inhibition. The presence of PDTC did not affect the enzyme activity on cultures treated 
with omeprazole but did negatively affect ALP activity on cultures treated with 
esomeprazole, inducing a higher decrease compared to the control. In the presence of 
lansoprazole, cultures supplemented with U0126 and SP600125 displayed activity 
decreases inferior to those seen in the control. On the other hand, PDTC and GO6983 
induced a higher inhibition.  
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4. Discussion 
 
    PPI are a class of drugs widely used in many pathological conditions, such as 
gastroesophageal reflux, dyspepsia and peptic ulcers. The mechanism of action relies in 
the inhibition of H+/K+ ATPases, responsible for gastric acid secretion. Osteoclasts are 
specialized cells that solubilize extracellular bone matrix through the production of acid, by 
proton pumps that belong to the same family as the gastric ones [75]. Thus, PPI appear 
as potential candidates to modulate osteoclast resorption activity, particularly in conditions 
associated with hyperactivation of these cells, such as bone osteolytic metastasis. Breast 
cancer is one of the most frequent tumours that originate bone metastasis, being the most 
common the osteolytic ones [47]. In this context, it seems relevant to assess the effects of 
PPI on human osteoclastogenesis in co-cultures of human osteoclasts and breast cancer 
cell lines. 
 
    The range of PPI concentrations used in this study was chosen according to 
concentrations found in human serum during therapeutic use of these molecules. It was 
seen that after a week of treatment with a daily dose of 20 mg omeprazole, the plasma 
maximum concentration was of about 1.1-3.2 µM, depending on the metabolizing capacity 
of the individual [87]. For esomeprazole, daily doses of 20 mg or 40 mg elicited a 
maximum concentration of 2.1 and 4.7 µM, respectively [88]. As for lansoprazole, after 
treatments with daily doses of 30 mg, plasma maximum concentration ranged between 
2.2 and 4.8 µM [87]. Thus, the observed values fall completely within the concentration 
range used in this study (10-9 – 10-3 M). However, it is important to notice that these are 
just mean values and that PPI pharmacokinetics depends on various factors.  
 
    Regarding the breast cancer cells, the tested cell lines are known to be associated with 
the development of bone metastasis. These lines were also selected by their different 
ability to express estrogen receptors, a factor known to be related with bone metastatic 
behavior of breast cancer cells [52, 53]. 
 
    In the first part of the work it was observed that the presence of the tested PPI under 
certain experimental conditions inhibits the proliferation/viability of breast cancer cell 
cultures. Thereby, indicating that those drugs have the ability to act directly on these cells. 
    More precisely, in SK-BR-3 cultures, cellular proliferation/viability inhibition occurred for 
concentrations higher than 10-5 M of each PPI. In the presence of 10-5 M omeprazole and 
esomeprazole, the cultures also displayed an increase in caspase-3 activity, suggesting 
that for those PPI, cellular proliferation/viability decrease may be due to apoptosis 
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mechanisms. In general, T47D line was less affected by PPI treatment. In this case, 
cellular growth inhibition occurred at concentrations slightly higher and particularly in the 
presence of lansoprazole. In general, these cultures exhibited lower caspase-3 activity 
values compared to SK-BR-3 cultures. Nevertheless, caspase-3 activity was only affected 
by the presence of the highest concentration (10-5 M) of lansoprazole.  
 
    In addition to the possible effects on the apoptosis mechanisms, the results observed 
on cultures of breast cancer cell lines might also be explained by the presence of vacuolar 
H+/ATPases in these cells. Acidity has been shown to have an important role in 
proliferation and metastatic behavior of cancer cells [83, 84]. Studies conducted on this 
matter revealed the presence of these proton pumps in the plasma membrane of human 
breast cancer cells with metastatic potential. However, these studies did not include SK-
BR-3 or T47D lines [78]. Following these studies, others have been performed in order to 
assess the potential of PPI to reverse the intrinsic resistance of human breast cancer cells 
to chemotherapy with promising results [76, 77]. 
 
    In the second part of the work it was performed an analysis of the effects of the different 
PPI tested in osteoclastogenesis, in co-cultures of PBMC and breast cancer cell lines.  
Globally, the presence of breast cancer cells, particularly T47D cells, greatly induced 
osteoclastogenesis in the co-cultures with PBMC. T47D line exhibited the highest 
osteoclastogenic potential and elicited the highest resorption ability. These results of 
osteoclastic stimulation are consistent with previous studies on the action of different 
breast cancer cell lines on bone cells, both on animal and human osteoclast cultures [53]. 
It was observed that the presence of the three PPI at certain concentrations inhibited 
osteoclastogenesis in both co-cultures, particularly in the presence of omeprazole. 
Generally, the effects observed presented a dose-dependent inhibition. Although the 
highest concentrations seemed to be toxic for osteoclastic cells (10-4 M and 10-3 M), the 
inhibition observed at lower concentrations appeared to be due to specific effects on the 
osteoclastogenic process, rather than to a significant decrease on the cellular viability. 
 
    Previous studies have reported that omeprazole could inhibit bone resorption at 
concentrations similar to those found in blood during therapeutic use of these molecules, 
likely because of inhibition of vacuolar H+/ATPases. In vitro, the presence of omeprazole 
inhibited bone resorption on rat cell cultures, and in vivo, treatment with omeprazole 
reduced the urinary excretion of calcium in patients with a history of gastric disease [81, 
82]. Up to our knowledge, there is no information regarding the ability of PPIs to modulate 
osteoclastogenesis promoted by breast cancer cells. 
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    Following the assessment of the osteoclastogenic effects of the different PPI in co-
cultures of PBMC and breast cancer cell lines, it was also carried out a characterization of 
the intracellular mechanisms involved in this process. For that, it was used the lowest 
common concentration of each PPI that elicited a significant anti-osteoclastogenic effect in 
each co-culture. In SK-BR-3 co-cultures it was used 10-6 M of the three PPI whereas in 
T47D co-cultures were used the following concentrations: 10-7 M omeprazole, 10-5 M 
esomeprazole and 10-7 M lansoprazole. 
 
   In control co-cultures of PBMC and SK-BR-3, the osteoclastogenic process was highly 
dependent on NFkB pathway and significantly dependent on MEK and JNK pathways. It 
was seen that the presence of omeprazole seemed not to affect the signaling pathways of 
co-cultures, compared to control. In the presence of esomeprazole, osteoclastogenesis 
appeared to be significantly dependent on NFkB pathway, while in the presence of 
lansoprazole this process appeared to be significantly dependent on PKC pathway. 
 
    In control co-cultures of PBMC and T47D, osteoclast differentiation was highly 
dependent on NFkB pathway and significantly dependent on PKC and JNK pathway. It 
was observed that in the presence of omeprazole and esomeprazole all the tested 
pathways seemed to become less important in osteoclastogenesis, compared to control. 
On the other hand, the presence of lansoprazole only affected the JNK pathway, making 
this pathway less important to the observed osteoclastic response.  
 
    It was also observed that the PPI tested are capable of directly act on osteoblastic 
hFOB cells. The presence of dexamethasone, an osteogenic enhancer, greatly induced 
ALP activity, as reported previously [89, 90, 91]. Cellular proliferation/viability of hFOB 
cultures maintained in the absence and presence of DEX decreased in the presence of 
the three PPI starting from the concentration 10-6 M. This inhibition was also seen for ALP 
activity, however, the percentage of inhibition was higher for ALP activity compared to that 
related to cell growth. This suggests that PPI effects are more likely to be due to specific 
changes on the cellular differentiation rather than to decreases on cellular viability due to 
toxic mechanisms. The inhibitory effects were more pronounced in the presence of 
omeprazole and lansoprazole. As observed in the previous culture systems, the highest 
tested concentrations of PPI appeared to be toxic for the cells.  
 
    In comparison with osteoclasts, significantly less attention has been paid to ATPases in 
osteoblasts. Osteoblastic cells have been shown to express some types of ATPases, 
namely, Na+/K+-ATPase and Ca+-ATPase, however, there is only indirect evidence of the 
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presence of vacuolar H+-ATPase in osteoblasts [86]. In vitro studies demonstrated that 
bafilomycin A1 and concanamycin A, which are potent and specific inhibitors of H+-
ATPases, dose-dependently inhibited the growth and changed the morphology of rat 
osteoblast cell lines [85, 86]. The present results are in agreement with this latter study, 
although the molecules do not have the same mechanism of action. 
 
    It was also carried out a characterization of the intracellular mechanisms involved in the 
osteoblastic response.  
    In control hFOB cultures maintained in the absence of DEX, cellular growth was highly 
dependent on NFkB pathway. The PKC and JNK pathways seemed to be more important 
for cellular growth in the presence of omeprazole and esomeprazole, whereas in the 
presence of lansoprazole, cellular proliferation/viability appeared to be significantly 
dependent on NFkB pathway.  
    In control cultures, ALP activity was highly dependent on NFkB and significantly 
dependent on MEK and PKC pathways. In the presence of omeprazole the enzyme 
activity appeared to be significantly dependent on JNK pathway. In the presence of 
esomeprazole PKC and JNK pathways are the most important, while the MEK pathway 
seemed to stand out in the presence of lansoprazole.  
     
    In control hFOB cultures maintained in presence of DEX, proliferation/viability was 
highly dependent on NFkB pathway. The pathways that appeared to be more important 
for cellular proliferation/viability in the presence of omeprazole were the PKC and JNK. In 
the presence of esomeprazole the MEK pathway was more important, while in the 
presence of lansoprazole cellular growth seemed significantly dependent on PKC 
pathway.  
    In control cultures, ALP activity was highly dependent on MEK and PKC pathways and 
significantly dependent on NFkB and JNK pathways. As observed in the cultures 
maintained in the absence of DEX, the ALP activity appeared to be significantly 
dependent on JNK pathway in the presence of omeprazole and esomeprazole. The NFkB 
pathway was also important in the presence of esomeprazole. The enzyme activity was 
significantly dependent on NFkB and PKC pathways.  
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5. Conclusion 
 
    The PPI, omeprazole, esomeprazole and lansoprazole, have the ability to negatively 
affect the osteoclastogenic process on co-cultures of osteoclasts and breast cancer cells, 
affecting not only osteoclastic cells differentiation but also their resorbing ability. This 
inhibition was depending on the identity and concentration of the tested molecule, and 
involved significant changes in different intracellular signaling pathways. PPI also inhibits 
cellular proliferation and viability of breast cancer cell cultures. This inhibition appeared to 
be, at least partially, due to an increase on apoptosis. Similarly, these compounds induced 
a decrease on osteoblastogenesis, an effect that might contribute to eventual disruption of 
normal bone cellular metabolic activities and consequently, lead to deleterious effects of 
these drugs in the bone tissue. Globally, these effects were observed at concentrations 
identical to those found in human serum during therapeutic use of these molecules.  
 
    This study contributed to a better understanding of the role of PPI in bone metabolism 
in the context of breast cancer bone metastases. In conclusion, PPI appeared to have the 
potential to control the destructive effects of osteolytic metastases, which might open 
doors to new therapeutic approaches regarding this pathological condition. 
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